Clinical trial
An Open-Label Study Evaluating the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
NCT06452316 is registered in ClinicalTrials.gov with Claris Biotherapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study Evaluating the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
- Lead sponsor
- Claris Biotherapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 15, 2024
- Completion date
- December 31, 2027
- Enrollment
- 75 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.